Opioid Abuse

Categories: Mental diseases

Aliases & Classifications for Opioid Abuse

MalaCards integrated aliases for Opioid Abuse:

Name: Opioid Abuse 12 54 15 70
Opioid-Related Disorders 44


External Ids:

Disease Ontology 12 DOID:11206
ICD9CM 34 305.5
MeSH 44 D009293
SNOMED-CT 67 5602001
ICD10 32 F11.1
UMLS 70 C0029095

Summaries for Opioid Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of opioid drugs despite negative consequences.

MalaCards based summary : Opioid Abuse, also known as opioid-related disorders, is related to chronic pain and opioid addiction. An important gene associated with Opioid Abuse is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Ribavirin and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and heart, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Opioid Abuse

Diseases related to Opioid Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 chronic pain 31.2 PNOC OPRM1
2 opioid addiction 30.1 PNOC OPRM1 OPRK1 OPRD1 DRD2 CCK
3 neonatal abstinence syndrome 29.8 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
4 alcohol use disorder 29.8 SLC6A3 OPRM1 DRD2 CCR6
5 substance abuse 29.5 SLC6A3 POMC PDYN OPRM1 DRD2 CYP2D6
6 psychotic disorder 29.0 SLC6A3 PDYN OPRM1 DRD2 CYP2D6 CCK
7 constipation 29.0 SAG PDYN OPRM1 OPRK1 CYP2D6 CCK
8 mental depression 28.6 SLC6A3 POMC DRD2 CYP2D6 CCR6
9 opiate dependence 28.5 SLC6A3 POMC PENK PDYN OPRM1 OPRL1
10 withdrawal disorder 28.3 SLC6A3 POMC PNOC PENK PDYN OPRM1
11 drug dependence 28.1 SLC6A3 POMC PNOC PENK PDYN OPRM1
12 alcohol dependence 27.9 SLC6A3 POMC PNOC PDYN OPRM1 OPRL1
13 schizophrenia 27.8 SLC6A3 POMC PNOC PDYN OPRM1 DRD2
14 pain agnosia 27.4 SAG POMC PNOC PENK PDYN OPRM1
15 chancroid 10.2 CCR6 CCR5
16 galactorrhea 10.1 DRD2 CYP2D6
17 hepatitis a 10.1
18 tardive dyskinesia 10.1 DRD2 CYP2D6
19 cryptococcal meningitis 10.0 MAPK10 CCR6 ARRB2
20 gastroparesis 10.0 DRD2 CYP2D6 CCK
21 hypogonadism 10.0
22 mood disorder 10.0
23 functionless pituitary adenoma 10.0 POMC CCK
24 barbiturate abuse 10.0 POMC OPRM1
25 ophthalmomyiasis 10.0 SAG CYP2D6
26 nasal cavity adenocarcinoma 9.9 POMC PDYN CCK
27 whim syndrome 9.9 SAG CCR6 ARRB2
28 impulse control disorder 9.9 SLC6A3 OPRM1 DRD2
29 ileus 9.9 POMC OPRM1 CCK
30 drug psychosis 9.9 SLC6A3 DRD2
31 pathological gambling 9.9 SLC6A3 OPRM1 DRD2
32 drug-induced mental disorder 9.9 SLC6A3 DRD2
33 articulation disorder 9.9 SLC6A3 DRD2 CCK
34 bestiality 9.9 SLC6A3 DRD2
35 substance-induced psychosis 9.9 SLC6A3 DRD2
36 fibromyalgia 9.9 POMC PNOC OPRM1
37 cocaine abuse 9.9 SLC6A3 OPRK1 DRD2
38 periodontitis, chronic 9.9
39 aging 9.9
40 polysubstance abuse 9.9
41 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 9.9
42 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.9
43 peripheral vascular disease 9.9
44 deficiency anemia 9.9
45 infective endocarditis 9.9
46 sexual disorder 9.9
47 cardiac arrest 9.9
48 endocarditis 9.9
49 pertussis 9.9
50 tetanus 9.9

Graphical network of the top 20 diseases related to Opioid Abuse:

Diseases related to Opioid Abuse

Symptoms & Phenotypes for Opioid Abuse

GenomeRNAi Phenotypes related to Opioid Abuse according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-2 9.47 MAPK10
2 Decreased viability GR00221-A-3 9.47 MAPK10
3 Decreased viability GR00249-S 9.47 MAPK10 NPFF OPRK1 OPRL1
4 Decreased viability GR00381-A-1 9.47 CYP2D6
5 Decreased viability GR00386-A-1 9.47 CCK ITIH4 OPRL1 POMC
6 Decreased viability GR00402-S-2 9.47 CYP2D6 OPRK1 OPRM1

MGI Mouse Phenotypes related to Opioid Abuse:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 ARRB2 CCK CCR5 DRD2 MAPK10 NPFF
2 homeostasis/metabolism MP:0005376 10.16 ARRB2 CCK CCR5 CCR6 DRD2 MAPK10
3 adipose tissue MP:0005375 9.91 ARRB2 DRD2 OPRM1 PDYN PENK POMC
4 integument MP:0010771 9.9 ARRB2 DRD2 OPRD1 OPRK1 OPRL1 OPRM1
5 nervous system MP:0003631 9.8 ARRB2 CCK CCR5 CCR6 DRD2 MAPK10
6 no phenotypic analysis MP:0003012 9.23 CCK DRD2 MAPK10 OPRD1 OPRM1 PDYN

Drugs & Therapeutics for Opioid Abuse

Drugs for Opioid Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ribavirin Approved Phase 4 36791-04-5 37542
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
Norepinephrine Approved Phase 4 51-41-2 439260
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Remifentanil Approved Phase 4 132875-61-7 60815
Acetaminophen Approved Phase 4 103-90-2 1983
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Cobicistat Approved Phase 4 1004316-88-4
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
Menthol Approved Phase 4 2216-51-5 16666
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
Nicotine Approved Phase 4 54-11-5 942 89594
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
Trichostatin A Experimental Phase 4 58880-19-6
25 Interferon alpha-2 Phase 4
26 Immunologic Factors Phase 4
27 Interferon-alpha Phase 4
28 Desvenlafaxine Succinate Phase 4 386750-22-7
29 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
30 Antipyretics Phase 4
31 Respiratory System Agents Phase 4
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
33 Antitussive Agents Phase 4
34 Anti-Arrhythmia Agents Phase 4
35 Sodium Channel Blockers Phase 4
36 Diuretics, Potassium Sparing Phase 4
37 Antimetabolites Phase 4
38 Anti-Bacterial Agents Phase 4
39 Antibiotics, Antitubercular Phase 4
40 Antitubercular Agents Phase 4
41 Cytochrome P-450 CYP3A Inhibitors Phase 4
42 Reverse Transcriptase Inhibitors Phase 4
43 Genvoya Phase 4
44 Sofosbuvir-velpatasvir drug combination Phase 4
45 Anti-Retroviral Agents Phase 4
46 Anti-HIV Agents Phase 4
47 Cytochrome P-450 Enzyme Inhibitors Phase 4
48 Hypolipidemic Agents Phase 4
49 Lipid Regulating Agents Phase 4
50 Anesthetics, Local Phase 4

Interventional clinical trials:

(show top 50) (show all 606)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
3 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
4 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
5 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
6 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
7 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
8 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
9 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
10 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
11 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
12 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
13 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
14 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
15 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
16 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
17 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
18 Buprenorphine Extended-release in Jail and at Re-entry: Open-label Randomized Controlled Trial vs. Daily Sublingual Buprenorphine-naloxone Completed NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
19 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
20 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
21 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
22 An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression Completed NCT02200406 Phase 4 Desvenlafaxine
23 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
24 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
25 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
26 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
27 Gabapentin Regimens and Their Effects on Opioid Consumption Completed NCT03334903 Phase 4 Gabapentin
28 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
29 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
30 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial Completed NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
31 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
32 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
33 Houston Emergency Engagement System for Youths and Adolescents Recruiting NCT04811014 Phase 4 Buprenorphine, Naloxone Drug Combination
34 Efficacy of Non-Opioid Analgesics in the Management of Pain Following Endoscopic Sinus Surgery: A Multi-Institutional Randomized Controlled Trial Recruiting NCT03783702 Phase 4 OxyCODONE 5 Mg Oral Tablet;Ibuprofen 600 Mg Oral Tablet;Acetaminophen 650 MG Oral Tablet
35 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Recruiting NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
36 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
37 The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis Recruiting NCT04033562 Phase 4 Lidocaine patch
38 Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study Recruiting NCT03949764 Phase 4 Sofosbuvir/velpatasvir (Epclusa®)
39 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Buprenorphine Naloxone;Methadone;Isoniazid;Rifapentine
40 Biomarkers of Disease and Response to Treatment in Opioid Addiction Active, not recruiting NCT02324725 Phase 4 Naltrexone
41 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Active, not recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
42 A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures Active, not recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
43 Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic Active, not recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
44 Overlapping Buprenorphine Initiation and Full Agonist Opioid Discontinuation Among Patients on High-dose Long-term Full Agonist Opioid Therapy Who Have Opioid Physical Dependence Not yet recruiting NCT04228250 Phase 4 Stepwise increase in buprenorphine while continuing full agonist opioid until buprenorphine reaches therapeutic dose
45 Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption Not yet recruiting NCT03534102 Phase 4 Improved Opioid-Tapering Instructions
46 The Impact of Opioid Misuse on Tobacco Smoking Cessation Not yet recruiting NCT03857139 Phase 4 Nicotine patch
47 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain. Terminated NCT02741076 Phase 4 Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER);Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
48 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
49 A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
50 Use of Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy: Evaluation of Postoperative Pain and Opioid Consumption Terminated NCT04495374 Phase 4 Pregabalin 300mg

Search NIH Clinical Center for Opioid Abuse

Cochrane evidence based reviews: opioid-related disorders

Genetic Tests for Opioid Abuse

Anatomical Context for Opioid Abuse

MalaCards organs/tissues related to Opioid Abuse:

Pituitary, Brain, Heart, Bone, Spinal Cord, Cortex, Kidney

Publications for Opioid Abuse

Articles related to Opioid Abuse:

(show top 50) (show all 1368)
# Title Authors PMID Year
International Narcotics Research--31st Conference. 61 54
16049839 2000
Comparison of Hospitalization Trends and Outcomes in Acute Myocardial Infarction Patients With Versus Without Opioid Use Disorder. 61
33454349 2021
Opioid abuse surveillance in patients with endocarditis. 61
32814665 2021
Peripheral nerve injury promotes morphine-seeking behavior in rats during extinction. 61
33453217 2021
Anterior insula stimulation increases pain threshold in humans: a pilot study. 61
33799301 2021
Variations in postoperative opioid prescribing by day of week and duration of hospital stay. 61
32684334 2021
Impact of motivational interviewing training on emergency department nurses' skills: A one-group pretest-posttest pilot study. 61
33735747 2021
Chronic Opioid Administration is Associated with Prevotella-dominated Dysbiosis in SIVmac251 Infected, cART-treated Macaques. 61
33788119 2021
Can a Neighborhood Fall Sick? Opioid Addiction, Collective Violence and Currents of Death in Contemporary India. 61
33715229 2021
Construct validity and reproducibility of the Prescription Opioid Misuse And Abuse Questionnaire (POMAQ). 61
33327799 2021
Optimizing Pain Control and Minimizing Opioid Use in Trauma Patients. 61
33725102 2021
Factors Predicting Chronic Opioid Use after Orthopedic Surgical Procedures. 61
33740360 2021
What Strategies Are Hospitals Adopting to Address the Opioid Epidemic? Evidence From a National Sample of Nonprofit Hospitals. 61
33176117 2021
Perceptions of Public Health Priorities and Accountability Among US Mayors. 61
33108978 2021
Attending and Resident Surgeon Perspectives and Prescribing Practices of Pain Medication During the Opioid Epidemic. 61
32843318 2021
Effect of Postoperative Analgesic Exposure to the Cannabinoid Receptor Agonist WIN55 on Osteogenic Differentiation and Spinal Fusion in Rats. 61
33759484 2021
HIV-1 Tat and morphine differentially disrupt pyramidal cell structure and function and spatial learning in hippocampal area CA1: Continuous versus interrupted morphine exposure. 61
33782102 2021
Gabapentin controlled substance status. 61
33674205 2021
Establishing the content validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ) among chronic pain patients. 61
33331184 2021
Factors mediating pain-related risk for opioid use disorder. 61
33524407 2021
Placental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome. 61
33711455 2021
Loperamide Induced Recurrent Torsades de Pointes: A Case Report. 61
33779357 2021
Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. 61
33629900 2021
An Analgesic Regimen for Opioid Reduction in Elective Plastic Surgery: A Randomized Prospective Study. 61
33565839 2021
Cost-Effectiveness of an Opioid Abuse-Prevention Program Using the Narcotics Information Management System in South Korea. 61
33518023 2021
Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry. 61
32918469 2021
Methadone: applications in pediatric anesthesiology and critical care medicine. 61
33432486 2021
Postdischarge Opioid Use after Total Hip and Total Knee Arthroplasty. 61
33553537 2021
Ten-year trend of opioid and nonopioid analgesic use in the French adult population. 61
32496599 2021
Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018. 61
33576816 2021
Opioid free anesthesia: evidence for short and long-term outcome. 61
32755088 2021
Calculating prescription rates and addiction probabilities for the four most commonly prescribed opioids and evaluating their impact on addiction using compartment modelling. 61
33585941 2021
Assessment of the impact of an opioid-specific education series on rates of medication-assisted treatment for opioid use disorder in veterans. 61
33289022 2021
Health Behavior Resources Available to Farmers in Rural Ohio. 61
33645459 2021
Understanding barriers to treatment among individuals not engaged in treatment who misuse opioids: A structural equation modeling approach. 61
33617738 2021
A Highly Efficacious Carfentanil Vaccine That Blunts Opioid-Induced Antinociception and Respiratory Depression. 61
33533592 2021
Revisiting the Provision of Pain Neuroscience Education: An Adjunct Intervention for Patients but a Primary Focus of Clinician Education. 61
33076759 2021
Epigenome-wide study of brain DNA methylation following acute opioid intoxication. 61
33667780 2021
Repeated morphine exposure activates synaptogenesis and other neuroplasticity-related gene networks in the dorsomedial prefrontal cortex of male and female rats. 61
33626484 2021
Zebrafish (Danio rerio) larvae show behavioral and embryonic development defects when exposed to opioids at embryo stage. 61
33621603 2021
Opioid-Induced Molecular and Cellular Plasticity of Ventral Tegmental Area Dopamine Neurons. 61
31964652 2021
Moving Toward Opioid-Free Breast Surgery: Regional Blocks and a Novel Technique. 61
33220899 2021
Effect of the morphine/heroin vaccine on opioid and non-opioid drug-induced antinociception in mice. 61
33171151 2021
Mid-term outcomes of anterior cruciate ligament reconstruction across age groups: A national database study. 61
33551608 2021
Opioid epidemics during the pandemic: Further insights to the same story. 61
33735423 2021
Tapentadol is the least common opioid found in admission urine drug-test results at an intensive outpatient opioid-use disorder treat-ment program in Ohio: A brief report. 61
33735424 2021
Opioid use in pregnant women with mental health-related disabilities. 61
33423110 2021
Administration and Prescription of Opioids in Emergency Departments: A Retrospective Study. 61
33643520 2021
Social housing promotes recovery of wheel running depressed by inflammatory pain and morphine withdrawal in male rats. 61
32949642 2021
33474874 2021

Variations for Opioid Abuse

Expression for Opioid Abuse

Search GEO for disease gene expression data for Opioid Abuse.

Pathways for Opioid Abuse

GO Terms for Opioid Abuse

Cellular components related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.24 SLC6A3 PNOC PENK PDYN OPRM1 OPRL1
2 integral component of plasma membrane GO:0005887 10.08 SLC6A3 OPRM1 OPRL1 OPRK1 OPRD1 DRD2
3 neuron projection GO:0043005 9.91 SLC6A3 OPRM1 OPRL1 OPRK1 OPRD1 MAPK10
4 axon GO:0030424 9.89 SLC6A3 PENK OPRM1 DRD2 CCK
5 neuronal cell body GO:0043025 9.88 SLC6A3 PNOC PENK PDYN OPRK1 CCK
6 dendrite GO:0030425 9.86 PNOC PENK PDYN OPRM1 OPRK1 NPFF
7 integral component of postsynaptic membrane GO:0099055 9.62 SLC6A3 OPRM1 OPRK1 DRD2
8 integral component of presynaptic membrane GO:0099056 9.55 SLC6A3 OPRM1 OPRK1 OPRD1 DRD2
9 dopaminergic synapse GO:0098691 9.51 SLC6A3 DRD2
10 perikaryon GO:0043204 9.5 PENK OPRM1 OPRK1 NPFF MAPK10 DRD2
11 spine apparatus GO:0097444 9.46 OPRM1 OPRD1
12 axon terminus GO:0043679 9.17 PNOC PENK PDYN OPRK1 OPRD1 NPFF

Biological processes related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.17 SAG POMC PNOC PENK OPRM1 OPRL1
2 G protein-coupled receptor signaling pathway GO:0007186 10 POMC PNOC PENK PDYN OPRM1 OPRL1
3 cytokine-mediated signaling pathway GO:0019221 9.98 POMC OPRM1 OPRD1 CCR5
4 chemical synaptic transmission GO:0007268 9.97 PNOC PENK PDYN OPRK1 NPFF
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.91 OPRM1 NPFF CCR6 CCR5
6 locomotory behavior GO:0007626 9.86 SLC6A3 PENK OPRK1 DRD2
7 response to ethanol GO:0045471 9.85 SLC6A3 PENK OPRM1 OPRK1 DRD2
8 cell chemotaxis GO:0060326 9.84 CCR6 CCR5 ARRB2
9 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.83 OPRM1 OPRL1 OPRK1 OPRD1
10 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.81 OPRM1 OPRK1 OPRD1
11 excitatory postsynaptic potential GO:0060079 9.81 OPRM1 NPFF DRD2 ARRB2
12 sensory perception of pain GO:0019233 9.8 PENK OPRM1 OPRL1 OPRK1
13 response to morphine GO:0043278 9.8 PENK OPRM1 OPRK1 NPFF DRD2
14 response to cocaine GO:0042220 9.78 SLC6A3 OPRM1 OPRK1 DRD2
15 response to nicotine GO:0035094 9.77 SLC6A3 PENK DRD2
16 eating behavior GO:0042755 9.77 OPRM1 OPRL1 OPRK1 OPRD1 CCK
17 response to radiation GO:0009314 9.76 PENK OPRM1 OPRK1
18 opioid receptor signaling pathway GO:0038003 9.73 OPRM1 OPRL1 OPRK1 OPRD1
19 regulation of sensory perception of pain GO:0051930 9.73 OPRM1 OPRL1 OPRK1 OPRD1 NPFF CCK
20 estrous cycle GO:0044849 9.72 OPRM1 OPRL1 OPRK1
21 G protein-coupled receptor internalization GO:0002031 9.71 SAG DRD2 ARRB2
22 negative regulation of cAMP-mediated signaling GO:0043951 9.69 OPRM1 OPRL1
23 response to iron ion GO:0010039 9.69 SLC6A3 DRD2
24 dendritic cell chemotaxis GO:0002407 9.68 CCR6 CCR5
25 behavior GO:0007610 9.68 OPRL1 OPRK1
26 negative regulation of cytosolic calcium ion concentration GO:0051481 9.68 OPRM1 DRD2
27 behavioral response to cocaine GO:0048148 9.67 OPRK1 DRD2
28 positive regulation of urine volume GO:0035810 9.67 OPRL1 DRD2
29 startle response GO:0001964 9.67 PENK DRD2
30 prepulse inhibition GO:0060134 9.66 SLC6A3 DRD2
31 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 OPRL1 DRD2
32 negative regulation of appetite GO:0032099 9.65 NPFF CCK
33 behavioral response to ethanol GO:0048149 9.65 OPRM1 DRD2
34 adenohypophysis development GO:0021984 9.64 SLC6A3 DRD2
35 positive regulation of behavioral fear response GO:2000987 9.63 PENK CCK
36 hyaloid vascular plexus regression GO:1990384 9.63 SLC6A3 DRD2
37 positive regulation of sensory perception of pain GO:1904058 9.62 OPRL1 CCK
38 acute inflammatory response to antigenic stimulus GO:0002438 9.62 OPRM1 NPFF
39 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.61 OPRM1 OPRL1
40 conditioned place preference GO:1990708 9.6 OPRL1 OPRK1
41 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.57 OPRM1 OPRK1
42 sensory perception GO:0007600 9.43 PNOC PENK PDYN OPRM1 OPRL1 OPRK1
43 neuropeptide signaling pathway GO:0007218 9.28 POMC PNOC PENK PDYN OPRM1 OPRL1

Molecular functions related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.98 CCR5 CCR6 DRD2 OPRD1 OPRK1 OPRL1
2 signaling receptor binding GO:0005102 9.88 SLC6A3 POMC NPFF DRD2 ARRB2
3 G protein-coupled receptor binding GO:0001664 9.71 SAG POMC NPFF ARRB2
4 peptide binding GO:0042277 9.67 OPRM1 OPRL1 OPRK1 OPRD1
5 neuropeptide hormone activity GO:0005184 9.62 PNOC PENK NPFF CCK
6 dopamine binding GO:0035240 9.49 SLC6A3 DRD2
7 receptor serine/threonine kinase binding GO:0033612 9.46 OPRK1 OPRD1
8 opioid receptor binding GO:0031628 9.43 PNOC PENK PDYN
9 opioid peptide activity GO:0001515 9.33 PNOC PENK PDYN
10 neuropeptide binding GO:0042923 9.26 OPRM1 OPRL1 OPRK1 OPRD1
11 opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Opioid Abuse

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....